Claire Friedman on Immunotherapy in Elderly Patients With Melanoma
Claire Friedman, MD, Memorial Sloan Kettering Cancer Center, discusses the promise of immunotherapy for elderly patients with melanoma.
Claire Friedman, MD, Memorial Sloan Kettering Cancer Center, discusses the promise of immunotherapy for elderly patients with melanoma.
A study was conducted at MSK that observed patients aged 80 or older who were treated with ipilimumab (Yervoy), pembrolizumab (Keytruda), nivolumab (Opdivo), or a combination of ipilimumab and nivolumab, between 2008 and 2015. The results, Friedman said, were very exciting, particularly for patients on ipilimumab, who had the best long-term survival data, with about 25% still alive today.
The study also revealed a plateau in the overall survival cure for elderly patients with melanoma, who traditionally had a poor prognosis.
Cemiplimab as Adjuvant Therapy Improves DFS in High-Risk Cutaneous Squamous Cell Carcinoma
January 20th 2025Adjuvant cemiplimab demonstrated a statistically significant improvement in DFS compared to placebo in post-surgical patients with high-risk CSCC, impacting post-operative care considerations.
Stopping ICIs at 1 or 2 Years May Not Compromise Survival in HNSCC
September 11th 2024This retrospective, population-based study shows strong efficacy across multiple patient subgroups and different lines of therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.
